AVBP · ArriVent BioPharma, Inc.

$28.22 -4.97 (-14.97%) At close · Jul 20

Market Cap

$1.32B

46.57M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Stuart Lutzker	President, Research and Development and Director	$515,779	—	—	$2,654,364	$247,574	$14,000	$3,431,717
Winston Kung	CFO	$492,417	—	—	$2,654,364	$246,287	$14,000	$3,407,068

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Winston Kung	CFO	$469,602	—	—	$1,190,331	$158,840	$13,800	$1,832,573
Stuart Lutzker	President, Research and Development and Director	$495,941	—	—	$297,457	$179,035	$13,534	$985,967

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Stuart Lutzker	President, Research and Development and Director	$476,867	—	—	$119,326	$219,359	$13,200	$828,752
Winston Kung	CFO	—	—	—	—	—	—	—

Key facts CIK 1868279 CUSIP 04272N102 13F (30d) 11 filings 11 filers Visit website Investor relations